ESSA Pharma Announces the Presentation of Additional Preclinical Data for EPI-7386 at the ESMO Virtual Congress 2020

On September 17, 2020 ESSA Pharma Inc. (Nasdaq: EPIX) (TSX-V: EPI), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, reported the presentation of data of ESSA’s clinical candidate, EPI-7386, at the ESMO (Free ESMO Whitepaper) Virtual Congress 2020 (Press release, ESSA, SEP 17, 2020, View Source [SID1234565320]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral poster presentation titled, "Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer" was published on Thursday, September 17th.

The studies highlight new information about EPI-7386 including:

In vitro cellular gene expression analyses demonstrate that EPI-7386:
In an in vitro VCaP model, combination treatment of EPI-7386 with enzalutamide, apalutamide or darolutamide display broader and deeper inhibition of AR-associated transcriptional activity than higher doses of each single agent alone.
Shows superior activity to enzalutamide in an AR-V7-driven cellular model by modulating both AR-FL and AR-V7-driven gene expression with or without the addition of an external androgen such as R1881.
"Previously, we presented in vitro data demonstrating that combination treatment of EPI-7386 with enzalutamide displays broader and deeper inhibition of AR-associated transcriptional activity than higher doses of each single agent alone. These newest transcriptomic analyses demonstrate a similar effect on inhibiting AR-regulated genes by combining EPI-7386 with apalutamide and darolutamide. These data provide additional rationale for studying the potential benefit of combining EPI-7386 with a variety of second-generation anti-androgens in earlier line prostate cancer patients," said Dr. David R. Parkinson, President & Chief Executive Officer.